DNB Asset Management AS Has $9.07 Million Stock Position in Baxter International Inc. $BAX

DNB Asset Management AS raised its position in shares of Baxter International Inc. (NYSE:BAX) by 304.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 398,118 shares of the medical instruments supplier’s stock after purchasing an additional 299,750 shares during the period. DNB Asset Management AS’s holdings in Baxter International were worth $9,065,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Mufg Securities Americas Inc. grew its position in Baxter International by 21.8% in the third quarter. Mufg Securities Americas Inc. now owns 13,850 shares of the medical instruments supplier’s stock worth $315,000 after acquiring an additional 2,477 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in Baxter International by 14.4% during the third quarter. EverSource Wealth Advisors LLC now owns 5,448 shares of the medical instruments supplier’s stock worth $124,000 after buying an additional 686 shares during the last quarter. Alteri Wealth LLC bought a new position in Baxter International during the third quarter valued at about $212,000. Tredje AP fonden lifted its position in shares of Baxter International by 62.3% in the third quarter. Tredje AP fonden now owns 119,622 shares of the medical instruments supplier’s stock worth $2,724,000 after buying an additional 45,940 shares during the last quarter. Finally, Raiffeisen Bank International AG increased its holdings in shares of Baxter International by 14.7% during the 3rd quarter. Raiffeisen Bank International AG now owns 19,286 shares of the medical instruments supplier’s stock valued at $432,000 after acquiring an additional 2,477 shares during the last quarter. Institutional investors and hedge funds own 90.19% of the company’s stock.

Baxter International Stock Performance

Shares of NYSE:BAX opened at $20.39 on Friday. The stock has a market capitalization of $10.49 billion, a price-to-earnings ratio of -11.02, a price-to-earnings-growth ratio of 1.42 and a beta of 0.59. The company has a debt-to-equity ratio of 1.55, a current ratio of 2.31 and a quick ratio of 1.56. The business’s fifty day moving average price is $20.19 and its two-hundred day moving average price is $21.03. Baxter International Inc. has a fifty-two week low of $17.40 and a fifty-two week high of $37.74.

Baxter International (NYSE:BAX) last released its quarterly earnings results on Thursday, February 12th. The medical instruments supplier reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.53 by ($0.09). Baxter International had a negative net margin of 8.51% and a positive return on equity of 16.95%. The firm had revenue of $2.97 billion during the quarter, compared to analyst estimates of $2.82 billion. During the same quarter last year, the firm earned $0.58 earnings per share. Baxter International’s quarterly revenue was up 8.0% on a year-over-year basis. Baxter International has set its FY 2026 guidance at 1.850-2.050 EPS. As a group, analysts predict that Baxter International Inc. will post 2.48 EPS for the current fiscal year.

Baxter International Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Stockholders of record on Friday, February 27th will be issued a dividend of $0.01 per share. This represents a $0.04 annualized dividend and a dividend yield of 0.2%. The ex-dividend date is Friday, February 27th. Baxter International’s dividend payout ratio is presently -2.16%.

Analysts Set New Price Targets

A number of brokerages have issued reports on BAX. Wall Street Zen cut Baxter International from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Weiss Ratings reissued a “sell (d)” rating on shares of Baxter International in a research report on Wednesday, January 21st. Morgan Stanley lowered their price target on Baxter International from $19.00 to $15.00 and set an “underweight” rating on the stock in a research report on Tuesday, December 2nd. Zacks Research cut Baxter International from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 20th. Finally, Barclays lowered their target price on Baxter International from $30.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, February 13th. Two analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus target price of $20.10.

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.